Retatrutide is a peptide that acts as a triple agonist, targeting the GIP, GLP-1, and glucagon receptors. It is studied in metabolic research and supplied as a reference compound for research use only.
What triple agonist means
The GLP-1 family has grown from single-target compounds to multi-target ones. Semaglutide targets one receptor, Tirzepatide targets two, and Retatrutide targets three: it adds the glucagon receptor to the GIP and GLP-1 targets.
How it is studied
In the laboratory, Retatrutide is studied in metabolic research as the most recent step in this peptide family. The research-grade compound is a study tool, not a therapeutic, supplied for research use only.
Browse research-grade peptides
Every Axis compound is third-party tested to 99.4%+ purity, with a certificate of analysis on every batch.
What to look for
As with any research peptide, a research-grade Retatrutide should ship with a batch-specific certificate of analysis confirming purity and identity.
Key takeaways
- Retatrutide is a triple agonist peptide.
- It targets the GIP, GLP-1, and glucagon receptors.
- It is the newest step in the GLP-1 family, studied in metabolic research.
- Research-grade Retatrutide is supplied for research use only.
A note on research use
The peptides supplied by Axis Peptide Labs are reference compounds for laboratory and research use only. They are intended for qualified researchers working in academic, institutional, and analytical settings. They are not drugs, foods, cosmetics, or medical products, and they are not intended for human or veterinary consumption. Documented identity and documented purity are what matter most when sourcing a compound, both of which are published on the Axis certificates of analysis page.
